Recombinant erythropoietin in clinical practice

Area of Science:

• Biotechnology and Pharmacology
• Hematology
• Nephrology

Background:

• Anemia is a common complication in chronic renal disease.
• Recombinant human erythropoietin (RHuEPO) has emerged as a key therapeutic agent.

Purpose of the Study:

• To review the historical and functional aspects of RHuEPO.
• To discuss the clinical applications of RHuEPO beyond anemia of chronic renal disease.
• To identify potential challenges associated with RHuEPO treatment.

Main Methods:

• Literature review of clinical studies and scientific publications.
• Analysis of historical data on erythropoietin development.
• Synthesis of information on RHuEPO's efficacy and safety in diverse conditions.

Main Results:

• RHuEPO has revolutionized anemia treatment in chronic renal disease.
• Clinical evidence supports RHuEPO's utility in non-uraemic conditions like hematological disorders, oncological diseases, prematurity, HIV infection, and perioperative settings.
• Potential issues and challenges in RHuEPO therapy have been identified.

Conclusions:

• RHuEPO is a versatile therapeutic agent with broad clinical applications.
• Understanding its historical context, function, and potential problems is crucial for optimal patient management.
• Further research may explore expanded uses and improved safety profiles of RHuEPO.